A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)

Completed

• Conditions: Colorectal Cancer; Non-Small Cell Lung Cancer

• Registration Number: NCT00388206
• Lead Sponsor: Genentech, Inc.

Brief Summary

This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in combination with first-line chemotherapy. Second-line metastatic CRC patients are also eligible. Patients who started their Avastin containing therapy \<4 months prior to enrollment are eligible.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-10-12
• Study First Submitted QC: 2006-10-13
• Study First Posted: 2006-10-16
• Study Start: 2006-11
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Status Verified: 2022-12
• Last Update Submitted: 2022-12-09
• Last Update Posted: 2022-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3998

Inclusion Criteria

• Signed Informed Consent Form
• Metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology)
• Eligible for Avastin as a component of intended therapy
• First-line chemotherapy (or second-line chemotherapy for CRC) plus Avastin initiated ≤ 4 months prior to study enrollment

Exclusion Criteria

• Any medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to provide informed consent or comply with the treatment and follow-up, as specified by the investigator
• Enrollment in a blinded, placebo-controlled bevacizumab trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified